AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30115183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (smartphone application and booklet)
Number of subjects: 42
Study 25194436 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine stress
Number of subjects: 200
Study 25194436 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 200
Study 25194436 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest and stress
Number of subjects: 200
Study 25194436 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 200
Study 22847995 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (using resistance bands)
Number of subjects: 15
Study 21951630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 848
Study 21951630 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 848
Study 21951630 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score
Number of subjects: 848
Study 21951630 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical SYNTAX score (CSS)
Number of subjects: 848
Study 18489935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 133
Study 18489935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 16223747 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH treatment (4 IU/m2/day for two years)
Number of subjects: 17
Study 16223747 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 17
Study 16223747 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH treatment
Number of subjects: 17
Study 16223747 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 12931293 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretta procedure using radiofrequency (RF) energy delivered to the distal lower esophageal sphincter (LES) and gastric cardia.
Number of subjects: 0
Study 12931293 — intervention group
Group type: COMPARATOR
Intervention: Sham control (not explicitly detailed in the abstract).
Number of subjects: 0
Study 11054340 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone (0.1%) administered four times daily
Number of subjects: 31
Study 11054340 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone (0.1%) administered twice daily
Number of subjects: 31
Study 8776496 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-dot patterns with no constraints
Number of subjects: 100
Study 8776496 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-dot patterns with constraints (no dot within fixed distance, uniform dot distribution)
Number of subjects: 100
Study 8776496 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of dots from 10 to 80
Number of subjects: 100
Study 8776496 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of dots per se
Number of subjects: 100
Study 1607030 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the minor pectoralis muscle
Number of subjects: 100
Study 1607030 — intervention group
Group type: COMPARATOR
Intervention: Removal of the minor pectoralis muscle
Number of subjects: 100
Study 7058425 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurette
Number of subjects: 40
Study 7058425 — intervention group
Group type: EXPERIMENTAL
Intervention: Vabra aspirator
Number of subjects: 40
Study 7058425 — intervention group
Group type: COMPARATOR
Intervention: Dilation and curettage (Control)
Number of subjects: 40
Study 7058425 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurette and Vabra aspirator
Number of subjects: 40
Study 31942669 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Training (HIT) - 4 × 30 s cycle sprints (2 min recovery) at 150% of maximum wattage achieved during assessment
Number of subjects: 12
Study 31942669 — intervention group
Group type: COMPARATOR
Intervention: Rest (Control)
Number of subjects: 12
Study 30343411 — intervention group
Group type: EXPERIMENTAL
Intervention: CDT plus Linfadren® (study group, n=25)
Number of subjects: 50
Study 30343411 — intervention group
Group type: COMPARATOR
Intervention: CDT (control group, n=25)
Number of subjects: 50
Study 28063976 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw-opening exercise (JE), n=13
Number of subjects: 25
Study 28063976 — intervention group
Group type: COMPARATOR
Intervention: Placebo exercise (PE), n=12
Number of subjects: 25
Study 26397721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 89
Study 23808594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine AP (Tropocer®) 90 mg once daily
Number of subjects: 0
Study 23808594 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine (Nimotop®) 30 mg three times daily
Number of subjects: 0
Study 20801601 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered care by family physicians
Number of subjects: 509
Study 20801601 — intervention group
Group type: COMPARATOR
Intervention: Patient-centered care by general internists
Number of subjects: 509
Study 18272244 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgenic anabolic steroids
Number of subjects: 0
Study 18272244 — intervention group
Group type: COMPARATOR
Intervention: Drug-free bodybuilders
Number of subjects: 0
Study 18272244 — intervention group
Group type: COMPARATOR
Intervention: Sedentary counterparts
Number of subjects: 0
Study 17476865 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 liver biopsies (specimens at least 15 mm in length with >= 4 portal tracts)
Number of subjects: 31
Study 17476865 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 liver biopsies (specimens at least 10 mm in length with >= 4 portal tracts)
Number of subjects: 31
Study 17476865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling discordance for portal fibrosis
Number of subjects: 31
Study 17476865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling discordance for zone 3 fibrosis
Number of subjects: 31
Study 17476865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling discordance for ballooning degeneration
Number of subjects: 31
Study 15090482 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicular lean soft tissue (ALST) estimates by dual‐energy X‐ray absorptiometry (DXA)
Number of subjects: 270
Study 15090482 — intervention group
Group type: EXPERIMENTAL
Intervention: ALST estimates with age included in the model
Number of subjects: 270
Study 15090482 — intervention group
Group type: EXPERIMENTAL
Intervention: ALST estimates with age, sex, and race included in the model
Number of subjects: 270
Study 15090482 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 applied to AN patients with BMI >16 kg/m(2)
Number of subjects: 270
Study 15090482 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA-based models
Number of subjects: 270
Study 12185401 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (200 mg)
Number of subjects: 8
Study 12185401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9501711 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein:creatinine ratio in spot morning urine samples
Number of subjects: 177
Study 7715221 — intervention group
Group type: COMPARATOR
Intervention: Standard transplantation (group I)
Number of subjects: 78
Study 7715221 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic transplantation (group II)
Number of subjects: 78
Study 2565098 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 40
Study 2565098 — intervention group
Group type: EXPERIMENTAL
Intervention: astemizole
Number of subjects: 40
Study 14057 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine for one year
Number of subjects: 43
Study 14057 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 31264119 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral lobectomy (Group I, n=127)
Number of subjects: 255
Study 31264119 — intervention group
Group type: COMPARATOR
Intervention: Total thyroidectomy (Group II, n=128)
Number of subjects: 255
Study 28483498 — intervention group
Group type: COMPARATOR
Intervention: 100% RDA (0.8g·kg‐1·d‐1) plus placebo injections
Number of subjects: 92
Study 28483498 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% RDA (0.8g·kg‐1·d‐1) plus 100mg testosterone enanthate injections
Number of subjects: 92
Study 28483498 — intervention group
Group type: EXPERIMENTAL
Intervention: 163% RDA (1.3g·kg‐1·d‐1) plus placebo injections
Number of subjects: 92
Study 28483498 — intervention group
Group type: EXPERIMENTAL
Intervention: 163% RDA (1.3g·kg‐1·d‐1) plus testosterone injections
Number of subjects: 92
Study 28483498 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 92
Study 26362001 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Number of subjects: 375
Study 26362001 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 375
Study 23904400 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus leuprolide acetate
Number of subjects: 220
Study 23904400 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 220
Study 21707189 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize contingency management (CM) treatment
Number of subjects: 78
Study 19092784 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 75 mg
Number of subjects: 12
Study 19092784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17156398 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (THAL)
Number of subjects: 668
Study 17156398 — intervention group
Group type: COMPARATOR
Intervention: No Thalidomide (Control)
Number of subjects: 668
Study 14704844 — intervention group
Group type: EXPERIMENTAL
Intervention: BCS-RT (breast-conserving surgery followed by adjuvant radiotherapy)
Number of subjects: 290
Study 14704844 — intervention group
Group type: COMPARATOR
Intervention: MRM (modified radical mastectomy)
Number of subjects: 290
Study 12096159 — intervention group
Group type: EXPERIMENTAL
Intervention: El Tren (The Train) board game intervention
Number of subjects: 0
Study 12096159 — intervention group
Group type: COMPARATOR
Intervention: Conventional social skills training
Number of subjects: 0
Study 10186932 — intervention group
Group type: EXPERIMENTAL
Intervention: Management training seminar held at a college for 1 year directed primarily at human resource managers.
Number of subjects: 20
Study 10186932 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not explicitly defined in the abstract).
Number of subjects: 20
Study 8617412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg)
Number of subjects: 8
Study 8617412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2568639 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zuclopenthixol daily
Number of subjects: 48
Study 2568639 — intervention group
Group type: COMPARATOR
Intervention: 1 mg haloperidol in the morning and 5 mg levomepromazine in the evening
Number of subjects: 48
Study 893737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine, 0.15 mg/kg
Number of subjects: 11
Study 893737 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propranolol, 0.1 mg/kg
Number of subjects: 11
Study 893737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine, 0.15 mg/kg after phentolamine infusion (0.01 or 0.02 mg/kg per minute)
Number of subjects: 11
Study 893737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine, 0.30 mg/kg
Number of subjects: 11
Study 893737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine, 0.60 mg/kg
Number of subjects: 11
Study 30820661 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoxia (FIO2 0.114)
Number of subjects: 8
Study 30820661 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (FIO2 0.152)
Number of subjects: 8
Study 30820661 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (FIO2 0.202)
Number of subjects: 8
Study 29197067 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health campaigns (CHCs)
Number of subjects: 4944
Study 29197067 — intervention group
Group type: COMPARATOR
Intervention: Health facilities
Number of subjects: 4944
Study 26672890 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dilution online haemodiafiltration (OL-HDF)
Number of subjects: 355
Study 26672890 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis
Number of subjects: 355
Study 25311446 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPS‐UP collaborative care
Number of subjects: 666
Study 25311446 — intervention group
Group type: COMPARATOR
Intervention: Usual collaborative primary care
Number of subjects: 666
Study 22313276 — intervention group
Group type: EXPERIMENTAL
Intervention: Opti‐Bond FL
Number of subjects: 50
Study 22313276 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 1 XT
Number of subjects: 50
Study 22313276 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ1
Number of subjects: 50
Study 20101007 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet plus weight management
Number of subjects: 144
Study 20101007 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet alone
Number of subjects: 144
Study 20101007 — intervention group
Group type: COMPARATOR
Intervention: Usual diet controls
Number of subjects: 144
Study 17729060 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (a long-acting β2-agonist) in combination with fluticasone propionate (an inhaled corticosteroid)
Number of subjects: 0
Study 17729060 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium bromide (an anticholinergic bronchodilator)
Number of subjects: 0
Study 15841623 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 U of BTX‐A
Number of subjects: 0
Study 15841623 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 U of BTX‐A
Number of subjects: 0
Study 15841623 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 U of BTX‐A
Number of subjects: 0
Study 15841623 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 U of BTX‐A
Number of subjects: 0
Study 15841623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11818765 — intervention group
Group type: COMPARATOR
Intervention: loratadine (20 mg)
Number of subjects: 14
Study 11818765 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (300 mg)
Number of subjects: 14
Study 11818765 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 9923421 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% maximum isometric contraction
Number of subjects: 12
Study 9923421 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% maximum isometric contraction
Number of subjects: 12
Study 9923421 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study 8678246 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (40 mg.kg‐1)
Number of subjects: 20
Study 8678246 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 2127959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 0
Study 2127959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 605761 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microgram/kg of naloxone
Number of subjects: 55
Study 605761 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microgram/kg of naloxone
Number of subjects: 55
Study 605761 — intervention group
Group type: COMPARATOR
Intervention: naloxone-treated patients
Number of subjects: 55
Study 605761 — intervention group
Group type: COMPARATOR
Intervention: naloxone
Number of subjects: 55
Study 31020900 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 30621
Study 31020900 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 30621
Study 31020900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30621
Study 31020900 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg vs Atorvastatin 80 mg
Number of subjects: 30621
Study 31020900 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney function as a predictor of cardiovascular outcomes
Number of subjects: 30621
Study 28755550 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 40
Study 28755550 — intervention group
Group type: COMPARATOR
Intervention: No intervention (placebo)
Number of subjects: 40
Study 28755550 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences (ACE)
Number of subjects: 40
Study 25775661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional meglumine antimoniate (MA) once a week
Number of subjects: 60
Study 25775661 — intervention group
Group type: COMPARATOR
Intervention: Topical application of trichloroacetic acid (TCA) 50% solution once weekly
Number of subjects: 60
Study 23153673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (INT)
Number of subjects: 0
Study 23153673 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CONV)
Number of subjects: 0
Study 23153673 — intervention group
Group type: EXPERIMENTAL
Intervention: GSPNE
Number of subjects: 0
Study 23153673 — intervention group
Group type: EXPERIMENTAL
Intervention: GSPNE adjusted for mean A1c
Number of subjects: 0
Study 22177370 — intervention group
Group type: EXPERIMENTAL
Intervention: Murraya koenigii and Tribulus terrestris-based oral formulation (2 capsules BID for 12 weeks)
Number of subjects: 46
Study 22177370 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (400 μg once daily for 12 weeks)
Number of subjects: 46
Study 20032914 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Recovery (GR) group
Number of subjects: 13
Study 20032914 — intervention group
Group type: COMPARATOR
Intervention: Poor Recovery (PR) group
Number of subjects: 13
Study 16267070 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation/atrial flutter (AF/AFL)
Number of subjects: 5983
Study 15618866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telephone intervention
Number of subjects: 0
Study 15618866 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10886048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g t.d.s., amoxycillin 500 mg t.d.s., and clarithromycin 400 mg b.d. (SAC regimen)
Number of subjects: 150
Study 10886048 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg o.m. with the same antimicrobial medications (LAC regimen)
Number of subjects: 150
Study 9309373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily
Number of subjects: 315
Study 9309373 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 400 mg twice daily
Number of subjects: 315
Study 8326053 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 31
Study 8326053 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg
Number of subjects: 31
Study 8326053 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification
Number of subjects: 31
Study 8326053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effects of MPH and behavior modification
Number of subjects: 31
Study 8326053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (baseline)
Number of subjects: 31
Study 2871860 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drug regimen: vincristine 2 mg m‐2 (maximum 2mg) followed by methotrexate 200 mgm‐2, given every three weeks for 54 weeks.
Number of subjects: 194
Study 2871860 — intervention group
Group type: COMPARATOR
Intervention: Three drug regimen: vincristine-methotrexate treatment alternating every three weeks with doxorubicin 60 mg m‐2 for 54 weeks.
Number of subjects: 194
Study 31667584 — intervention group
Group type: EXPERIMENTAL
Intervention: PMTS-guided in-plane epidural access
Number of subjects: 50
Study 31667584 — intervention group
Group type: COMPARATOR
Intervention: PMSS-guided in-plane epidural access
Number of subjects: 50
Study 31667584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 29343817 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (BMI ≥18.5 to <25)
Number of subjects: 10000
Study 29343817 — intervention group
Group type: EXPERIMENTAL
Intervention: Every additional unit of BMI over 25 kg/m2
Number of subjects: 10000
Study 29343817 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints (development of new macroalbuminuria, doubling of creatinine, end stage renal disease, or renal death)
Number of subjects: 10000
Study 28225522 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 strength training session per week (1W)
Number of subjects: 35
Study 28225522 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 strength training sessions per week (2W)
Number of subjects: 35
Study 28225522 — intervention group
Group type: COMPARATOR
Intervention: 1 strength training session every second week (0.5W)
Number of subjects: 35
Study 28225522 — intervention group
Group type: COMPARATOR
Intervention: 2W vs 1W
Number of subjects: 35
Study 28225522 — intervention group
Group type: COMPARATOR
Intervention: 1W and 2W vs 0.5W
Number of subjects: 35
Study 25074637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrexidine (DAR-0100A) 15 mg/150 ml of normal saline administered intravenously over 30 min
Number of subjects: 16
Study 25074637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrexidine (DAR-0100A)
Number of subjects: 16
Study 25074637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23307890 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen mentoring (experimental group)
Number of subjects: 0
Study 23307890 — intervention group
Group type: COMPARATOR
Intervention: Adult teacher (control group)
Number of subjects: 0
Study 21947987 — intervention group
Group type: EXPERIMENTAL
Intervention: Westminster positive protocol
Number of subjects: 114
Study 21947987 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 21947987 — intervention group
Group type: COMPARATOR
Intervention: Italian negative group
Number of subjects: 114
Study 18174862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent human-bovine reassortant rotavirus vaccine
Number of subjects: 178
Study 18174862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178